Spruce Biosciences (SPRB) announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Spruce Biosciences. Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. are acting as joint book-running managers and Jones and Craig-Hallum are acting as co-managers for the proposed offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Biotech Alert: Searches spiking for these stocks today
- Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline
- Clear Regulatory Path and Strong Cash Position Underpin Buy Rating on Spruce Biosciences and Tralesinidase Alfa
- Spruce Biosciences price target lowered to $170 from $180 at Citizens
- Spruce Biosciences Updates ATM Agreement, Strengthens Leadership Team